Blome Christine, Maares Jürgen, Diepgen Thomas, Jeffrustenbach Stephan, Augustin Matthias
CVderm - German Center for Health Services Research in Dermatology, University Clinics of Hamburg, Hamburg, Germany.
Contact Dermatitis. 2009 Jul;61(1):39-45. doi: 10.1111/j.1600-0536.2009.01536.x.
The assessment of patient-relevant treatment benefit gains importance in treatment evaluation. The 'Patient Benefit Index' (PBI) is a validated instrument for the assessment of such benefits in patients with skin diseases. Patients rate the importance of specific treatment needs before treatment and benefits achieved after treatment. To date, no specific instrument for chronic hand eczema (CHE) has been published.
Development and validation of a specific PBI for treatment evaluation in patients with CHE.
Items reflecting disease burden and treatment needs were collected in 20 patients with CHE. Relevant items were selected by an expert panel of dermatologists, psychologists, and patients. The resulting 'Patient Benefit Index for chronic hand eczema' (PBI-HE) was validated in an open label treatment study with alitretinoin in n = 249 patients.
Cronbach's alpha was 0.93. High convergent validity was demonstrated for clinical improvement and treatment success (Spearman r = 0.60-0.78, P < 0.001); 84.3% of patients reached a PBI >or= 1, indicating more than minimum patient-relevant benefit of alitretinoin. Feasibility was high, with a rate of missing data < 1%.
The PBI-HE is a feasible, reliable, and valid instrument for the assessment of patient-relevant treatment benefits in CHE.
在治疗评估中，对与患者相关的治疗益处的评估变得愈发重要。“患者益处指数”（PBI）是一种经过验证的工具，用于评估皮肤病患者的此类益处。患者在治疗前对特定治疗需求的重要性进行评分，并在治疗后对所取得的益处进行评分。迄今为止，尚未发表针对慢性手部湿疹（CHE）的特定工具。
开发并验证一种用于评估CHE患者治疗效果的特定PBI。
收集了20例CHE患者反映疾病负担和治疗需求的项目。由皮肤科医生、心理学家和患者组成的专家小组挑选出相关项目。在一项使用阿利维A酸治疗n = 249例患者的开放标签治疗研究中，对所得的“慢性手部湿疹患者益处指数”（PBI-HE）进行了验证。
Cronbach's α为0.93。临床改善和治疗成功显示出高收敛效度（Spearman r = 0.60 - 0.78，P < 0.001）；84.3%的患者PBI≥1，表明阿利维A酸具有超过最低限度的与患者相关的益处。可行性高，缺失数据率<1%。
PBI-HE是一种可行、可靠且有效的工具，用于评估CHE患者与患者相关的治疗益处。
